• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组人凝血因子VIII(rFVIII)失活与溶液中聚集的相关性。

Correlation of rFVIII inactivation with aggregation in solution.

作者信息

Wang Wei, Kelner Drew N

机构信息

Analytics & Formulation, Process Sciences, Biotechnology, Bayer Corp., 800 Dwight Way, Berkeley, California 94701, USA.

出版信息

Pharm Res. 2003 Apr;20(4):693-700. doi: 10.1023/a:1023271405005.

DOI:10.1023/a:1023271405005
PMID:12739780
Abstract

PURPOSE

This study was designed to investigate the stability of recombinant FVIII (rFVIII) in solution at different pHs and to probe the cause(s) of rFVIII inactivation under accelerated storage conditions.

METHODS

Aqueous stability samples of full-length rFVIII at different pHs were incubated at 40 degrees C for several days and analyzed by the one-stage clotting assay. SEC-HPLC, SDS-PAGE, and UV spectrophotometry.

RESULTS

Incubation of liquid rFVIII at 40 degrees C inactivated the protein rapidly and linearly with time on a semi-log scale at all pHs, suggesting a first order or pseudo first order process. A U-shaped relationship was found between the rate constant for loss of rFVIII activity and the solution pH. The minimal rate of inactivation was found between pH 6.6 and 7.0 with a half-life of approximately 4 days. The SEC-HPLC results indicated pH-dependent aggregation of rFVIII during incubation. It was found that the disappearance of monomeric rFVIII by SEC-HPLC correlated with the loss of rFVIII activity (r2 = 0.97). Both the SDS-PAGE and UV results confirmed the aggregation pathway of rFVIII. In addition, the SDS-PAGE results suggest involvement of three aggregation mechanisms--disulfide-bond formation/exchange, non-reducible crosslinking, and physical interactions.

CONCLUSIONS

The full-length rFVIII is unstable in solution at 40 degrees C and loses activity rapidly through a first order or pseudo first order aggregation process, which consists of both physical and chemical pathways. SEC-HPLC may be used in monitoring rFVIII stability studies in lieu of the clotting assay under the incubation conditions used in this study.

摘要

目的

本研究旨在调查重组凝血因子VIII(rFVIII)在不同pH值溶液中的稳定性,并探究加速储存条件下rFVIII失活的原因。

方法

将不同pH值的全长rFVIII的水性稳定性样品在40℃孵育数天,并通过一步凝血试验、尺寸排阻色谱-高效液相色谱(SEC-HPLC)、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和紫外分光光度法进行分析。

结果

在所有pH值下,将液体rFVIII在40℃孵育会使蛋白质迅速失活,且在半对数尺度上随时间呈线性变化,表明这是一个一级或准一级过程。发现rFVIII活性丧失的速率常数与溶液pH值之间呈U形关系。在pH 6.6至7.0之间发现失活速率最小,半衰期约为4天。SEC-HPLC结果表明孵育期间rFVIII存在pH依赖性聚集。发现通过SEC-HPLC检测到的单体rFVIII的消失与rFVIII活性的丧失相关(r2 = 0.97)。SDS-PAGE和紫外结果均证实了rFVIII的聚集途径。此外,SDS-PAGE结果表明涉及三种聚集机制——二硫键形成/交换、不可还原交联和物理相互作用。

结论

全长rFVIII在40℃的溶液中不稳定,通过一级或准一级聚集过程迅速丧失活性,该过程包括物理和化学途径。在本研究使用的孵育条件下,SEC-HPLC可用于监测rFVIII稳定性研究,以替代凝血试验。

相似文献

1
Correlation of rFVIII inactivation with aggregation in solution.重组人凝血因子VIII(rFVIII)失活与溶液中聚集的相关性。
Pharm Res. 2003 Apr;20(4):693-700. doi: 10.1023/a:1023271405005.
2
How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-Domain.全长 FVIII 如何受益于其异质性 - B 结构域作用的见解。
Pharm Res. 2019 Apr 1;36(5):77. doi: 10.1007/s11095-019-2599-2.
3
Aggregation kinetics of recombinant human FVIII (rFVIII).重组人凝血因子VIII(rFVIII)的聚集动力学
J Pharm Sci. 2005 Sep;94(9):2023-9. doi: 10.1002/jps.20432.
4
Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII.中国仓鼠卵巢细胞产生的重组凝血因子VIII酪氨酸硫酸化的异质性。
Biochemistry. 1991 Feb 12;30(6):1533-7. doi: 10.1021/bi00220a013.
5
Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.B结构域在活化蛋白C和活化因子X对活化凝血因子VIII的蛋白水解失活中的作用。
Blood Coagul Fibrinolysis. 2006 Jul;17(5):379-88. doi: 10.1097/01.mbc.0000233368.95733.3c.
6
Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.市售因子 VIII 产品的比较分析:重组产品在可溶性蛋白聚集体和亚可见颗粒方面并不相同。
J Thromb Haemost. 2018 Jun;16(6):1176-1181. doi: 10.1111/jth.14125. Epub 2018 May 11.
7
Recombinant factor VIII protein aggregation and adsorption at the liquid-solid interface.重组因子VIII蛋白在液固界面的聚集与吸附。
J Colloid Interface Sci. 2022 Dec 15;628(Pt A):820-828. doi: 10.1016/j.jcis.2022.07.161. Epub 2022 Jul 28.
8
Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII.重组凝血因子VIII(FVIII)重链和轻链的合成以及FVIII活性形式的重构。
Exp Mol Med. 1999 Jun 30;31(2):95-100. doi: 10.1038/emm.1999.16.
9
Evaluation of recombinant factor VIII (Kogenate) stability for continuous infusion using a minipump infusion device.使用微型泵输注装置评估重组因子VIII(科跃奇)连续输注的稳定性。
Haemophilia. 1998 Nov;4(6):785-9. doi: 10.1046/j.1365-2516.1998.00204.x.
10
Expression and characterization of a mutant recombinant blood coagulation factor VIII (rFVIII (m)).一种突变重组凝血因子VIII(rFVIII (m))的表达与特性分析
Exp Mol Med. 2002 Jul 31;34(3):233-8. doi: 10.1038/emm.2002.32.

引用本文的文献

1
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.高度聚集的抗体疗法可以增强体外固有和晚期 T 细胞免疫反应。
J Biol Chem. 2012 Jul 20;287(30):25266-79. doi: 10.1074/jbc.M111.330902. Epub 2012 May 14.
2
O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.O-磷酸-L-丝氨酸,用于B结构域缺失重组因子VIII的多功能辅料。
AAPS J. 2007 Jun 29;9(2):E251-9. doi: 10.1208/aapsj0902028.
3
Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

本文引用的文献

1
A study of the cation- and pH-dependent stability of factors V and VIII in plasma.血浆中因子V和因子VIII的阳离子及pH依赖性稳定性研究。
Thromb Diath Haemorrh. 1965 Sep 1;14(1-2):32-51.
2
Studies of temperature and pH stability of human antihaemophilic factor (AHF) in plasma and in a concentrate.
Br J Haematol. 1959 Apr;5(2):169-76. doi: 10.1111/j.1365-2141.1959.tb04022.x.
3
Conformational origin of the aggregation of recombinant human factor VIII.重组人凝血因子VIII聚集的构象起源
聚集对重组人凝血因子VIII在甲型血友病小鼠体内免疫原性的影响。
J Pharm Sci. 2006 Feb;95(2):358-71. doi: 10.1002/jps.20529.
4
Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII).脂质结合区域(2303 - 2332)参与重组人凝血因子VIII(rFVIII)的聚集。
J Pharm Sci. 2005 Jun;94(6):1288-99. doi: 10.1002/jps.20340.
5
Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.给予重组因子VIII-O-磷酸-L-丝氨酸复合物后,血友病A小鼠体内低水平抑制剂的产生
J Biol Chem. 2005 May 6;280(18):17593-600. doi: 10.1074/jbc.M500163200. Epub 2005 Feb 23.
Biochemistry. 2001 Jan 16;40(2):586-95. doi: 10.1021/bi001547t.
4
Recombinant factor VIII SQ--stability of VIII: C in homogenates from porcine, monkey and human subcutaneous tissue.
J Pharm Pharmacol. 2000 Jul;52(7):797-805. doi: 10.1211/0022357001774651.
5
Loss of factor VIII activity during storage in PVC containers due to adsorption.由于吸附作用,在聚氯乙烯容器中储存期间因子VIII活性丧失。
Haemophilia. 2000 Mar;6(2):89-92. doi: 10.1046/j.1365-2516.2000.00382.x.
6
Inhibition of aggregation side reactions during in vitro protein folding.
Methods Enzymol. 1999;309:217-36. doi: 10.1016/s0076-6879(99)09017-5.
7
The life cycle of coagulation factor VIII in view of its structure and function.从凝血因子VIII的结构和功能来看其生命周期。
Blood. 1998 Dec 1;92(11):3983-96.
8
A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma.天然状态的短暂扩张先于重组人干扰素-γ的聚集。
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14142-6. doi: 10.1073/pnas.95.24.14142.
9
Aggregation of recombinant human interferon gamma: kinetics and structural transitions.重组人干扰素γ的聚集:动力学与结构转变
J Pharm Sci. 1998 Sep;87(9):1069-76. doi: 10.1021/js9801384.
10
Protein aggregation: folding aggregates, inclusion bodies and amyloid.蛋白质聚集:折叠聚集体、包涵体与淀粉样蛋白。
Fold Des. 1998;3(1):R9-23. doi: 10.1016/S1359-0278(98)00002-9.